Skip to main content

Apogenix to Present at Five Upcoming International Conferences

HEIDELBERG, GERMANY / ACCESSWIRE / October 18, 2018 / Apogenix, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, announced today that company representatives will attend several upcoming international conferences. In a total of five presentations, Apogenix will give updates on its hexavalent TNF superfamily receptor agonists (HERA-ligands) as well as its phase III-ready lead drug candidate asunercept.

Joint BioRN & Ci3 Annual Conference 2018: Immunotherapy and beyond - The next generation of cancer treatment (October 25, 2018)
Venue: Merck KGaA, Darmstadt, Germany
Presentation on October 25, 2:55 pm: "Apogenix' TNFR-Mediated Signaling Modulators - Innovative Immuno-Oncology Therapeutics"
Presenter: Thomas Hoeger, Ph.D., CEO

World Immunotherapy Congress 2018 (October 29 - 31, 2018)
Venue: Basel Congress Center, Basel, Switzerland
Presentation on October 30, 3:35 pm: "Hexavalent TNFR-SF Agonists for Cancer Immunotherapy: HERA-CD40L, HERA-CD27L and Beyond"
Presenter: Oliver Hill, Ph.D., VP Molecular Biology/Protein Engineering

BIO-Europe (November 5 - 7, 2018)
Venue: Bella Center Copenhagen, Copenhagen, Denmark
Attendees: Thomas Hoeger, Ph.D., CEO; Juergen Gamer, Ph.D., VP Business Development

SITC 33rd Annual Meeting (November 7 - 11, 2018)
Venue: Walter E. Washington Convention Center, Washington, D.C., USA
Presentation on November 11, 8:05 - 10:30 am: "Immuno-oncology tHERApy with HERA-GITRL: the novel hexavalent human GITR agonist activates T cells and promotes anti-tumor efficacy independent of Fc-functionality" (Session: Next Generation Bispecifics and Antibody-Like Molecules)
Presenter: David Richards, Ph.D., Head of Immunology

10th Annual PEGS Europe (November 12 - 16, 2018)
Venue: Lisbon Congress Center, Lisbon, Portugal
Presentation on November 15, 4:00 pm: "HERA: Engineering Next-Generation TNFR-SF Agonists for Cancer Immunotherapy"
Presenter: Oliver Hill, Ph.D., VP Molecular Biology/Protein Engineering

SNO 23rd Annual Meeting and Education Day (November 15 - 18, 2018)
Venue: Marriott Hotel, New Orleans, LA, USA
Poster Presentation on November 16, 7:30 - 9:30 pm: "Asunercept plus radiotherapy in relapsed glioblastoma. Update on five years overall survival of study NCT01071837 and development of a Population-PK - Tumor Growth Inhibition - Survival Model" (Poster #ATIM-13)
Presenter: Harald Fricke, M.D., CMO

About Apogenix
Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The Heidelberg, Germany-based company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor (TNF) superfamily-dependent signaling pathways, thereby restoring the immune response against tumors. Checkpoint inhibitor asunercept, the company's lead immuno-oncology candidate, is in late-stage clinical development. In 2017, asunercept received PRIME (PRIority MEdicines) designation by the European Medicines Agency (EMA) for the treatment of glioblastoma. Based on its proprietary technology platform for the construction of novel hexavalent TNF superfamily receptor agonists (HERA-ligands), Apogenix develops CD40, CD27, GITR, HVEM, 4-1BB, and OX40 receptor agonists for cancer immunotherapy.

In 2015, asunercept was exclusively licensed to CANbridge Life Sciences for the development and commercialization for the treatment of glioblastoma in China, Macao, Hong Kong, and Taiwan. CANbridge has received approval by the China Food and Drug Administration for a pivotal phase II/III trial with asunercept (CAN008) in glioblastoma in China. The HERA-TRAIL receptor agonist program was partnered with AbbVie in 2014. In 2017, AbbVie initiated a phase I trial with this HERA-TRAIL receptor agonist (ABBV-621) in patients suffering from solid tumors, non-Hodgkins's lymphoma, or acute myeloid leukemia.

Contacts
Thomas Hoeger, Ph.D., CEO
Juergen Gamer, Ph.D., VP Business Development
Apogenix AG
Phone: +49 6221 58608-0
E-Mail: contact@apogenix.com
Web: www.apogenix.com

Media Contacts
Katja Arnold
Andreas Jungfer
MC Services AG
Phone: +49 89 210228-0
E-Mail: apogenix@mc-services.eu

SOURCE: Apogenix

View source version on accesswire.com:
https://www.accesswire.com/525720/Apogenix-to-Present-at-Five-Upcoming-International-Conferences

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.